Click here: to donate by Credit Card
Or here: to donate by PayPal
Or by mail to: Free Republic, LLC - PO Box 9771 - Fresno, CA 93794
Thank you very much and God bless you.
Posted on 09/07/2026 9:54:13 PM PDT by SeekAndFind
In a promising development for pancreatic cancer treatment, scientists at Spain's National Cancer Research Centre (CNIO) have successfully eliminated pancreatic tumors in mice using a triple-combination therapy.
The findings were published in the Proceedings of the National Academy of Sciences (PNAS) on January 25, 2026. This represents a significant advance in tackling pancreatic ductal adenocarcinoma (PDAC), one of the deadliest cancers. PDAC has one of the lowest survival rates, with over 10,300 new patients diagnosed annually in Spain alone, and a devastating five-year survival rate of less than 10%.
The team was led by Dr. Mariano Barbacid, head of the Experimental Oncology Group at CNIO. The study was based on the understanding that current drugs for pancreatic cancer, including recently approved KRAS inhibitors, often lose effectiveness within months due to the development of resistance. To address this, the research team developed a therapeutic approach that simultaneously targets three critical points in the KRAS signaling pathway, making it harder for tumors to escape treatment.
By blocking downstream (RAF1), upstream (EGFR), and orthogonal (STAT3) signaling pathways at the same time, the therapy prevented tumors from developing resistance. This strategy shut down multiple escape routes for tumors.
The therapy was tested in three different mouse models of pancreatic ductal adenocarcinoma. The treatment induced significant and lasting tumor regression, with no evidence of resistance for over 200 days post-treatment. The triple combination was well tolerated, with no significant toxicities reported. This marks a potential milestone in pancreatic cancer research.
“These results open a path to designing combination therapies that could improve survival for patients with pancreatic ductal adenocarcinoma,” the authors note in PNAS.
Despite these unprecedented findings, Dr. Barbacid emphasizes caution regarding immediate clinical applications.
"Although experimental results like those described here have never been obtained before, we are not yet in a position to carry out clinical trials with the triple therapy," he said in a statement.
The researchers acknowledge that optimizing the therapy for human use will require careful study. Still, the authors offer hope: "Despite current limitations, these results could open the door to new therapeutic options to improve the clinical outcome of patients with pancreatic ductal adenocarcinoma in the not-too-distant future."
According to a statement by CNIO, the study received support from several prestigious organizations, including the CRIS Cancer Foundation, the European Research Council (ERC), the Spanish State Research Agency, Next Generation EU funds, the Biomedical Research Networking Center (CIBERONC), and the Carlos III Health Institute.
The CNIO is a leading public research institution under the Ministry of Science, Innovation, and Universities. It is recognized as one of Europe’s foremost cancer research centers and has been accredited as a Severo Ochoa Center of Excellence since 2011.
Dr. Mariano Barbacid is a world-renowned Spanish molecular biochemist and a pioneer in the field of molecular oncology. He is best known for his 1982 discovery of the first human oncogene, HRAS.
In recognition of his contributions to science, Dr. Barbacid was awarded the Echegaray Medal in November 2020, the highest scientific honor given by the Royal Academy of Exact, Physical and Natural Sciences.
Liaki V, Barrambana S, Kostopoulou M, et al., Barbacid M. A targeted combination therapy achieves effective pancreatic cancer regression and prevents tumor resistance. PNAS, 122(49): e2523039122. https://doi.org/10.1073/pnas.2523039122
(Rh/VK)
|
|
Click here: to donate by Credit Card Or here: to donate by PayPal Or by mail to: Free Republic, LLC - PO Box 9771 - Fresno, CA 93794 Thank you very much and God bless you. |
More here:
https://thelifesciencesmagazine.com/pancreatic-cancer-cure/
and here:
and here:
and here:
https://medicalxpress.com/news/2026-02-pancreatic-tumors-mice-resistance.html
Mice are so lucky... they get all the good meds!
JK. Here's to hoping it leads to eliminating pancreatic cancer in human beans. 🍻
But we can’t remember what it is.
JK!!! I have friends who have died from ALS and dementia. I know it’s not a laughing matter but sometimes it helps.
Maybe it's time to call it.
One reason why 3 or 4 meds given simultaneously work so well is because it is nearly impossible to get the 4 simultaneous mutations necessary which would allow a tumor to keep on growing in the face of treatment.
That’s why anti-HIV “cocktails”(no pun intended) use 3 or 4 different chemicals simultaneously which inhibit different HIV survival biochemical pathways.
Thanks. I’m always in awe of what these scientists conceive as new ways to battle disease. This triple therapy to block three signaling pathways — wow. I hope it works out for humans.
It would be great if people were periodically screened for it, since virtually the only time its found is late stage because symptoms are similar to so many other things. Tht would also increase survival rates, catching it early before it renders the organ almost useless or the cancer spreads tocother places and then its not just pancreatic cancer to deal with.
Have you suggested Ivermectin and mebendazole
https://pmc.ncbi.nlm.nih.gov/articles/PMC9739667/
https://pmc.ncbi.nlm.nih.gov/articles/PMC9459089/
https://rumble.com/v6gs91v-cancers-repurposed-drugs-dr-makis.html?e9s=src_v1_clr%2Csrc_v1_ucp_a
Well, yeah, after we induce cancer!
The thing about metastatic cancer is it’s still the same cancer. So if cancer A spreads to other organs/tissues, it’s still just cancer A and responds to the same chemo the same way. The later you catch it, the more damage there is to begin with and the more total cancer to eradicate, so more likelihood some patch somewhere will develop resistance. But otherwise it is still just one treatment.
There might be more surgical implications, for sure, and more complications.
One of these days I will write a story about a future race of super intelligent mice that live long lives and are impervious to every known disease, long after the human race has disappeared.
They believe humans were gods that gave them the long life and super resilience, and worship them.
But a single historian and archeologist will discover the tragic secret.
Will he inform the rest of the people or no?.........
There isn’t any specific screening for PC.
Isn’t that the kids book. THE RATS OF NIHM
And they must be the healthiest animals in the world.
bump for later
I’ll buy it. Let me know when it’s out.
Never heard of it........
Disclaimer: Opinions posted on Free Republic are those of the individual posters and do not necessarily represent the opinion of Free Republic or its management. All materials posted herein are protected by copyright law and the exemption for fair use of copyrighted works.